Items tagged with Scientific research

This 'bacteria hunter' discovered the causes of tuberculosis, anthrax, and cholera (post)

Robert Koch, a founding father of microbiology, used hands-on experiments in the 1800s to find the bacteria behind three of history's deadliest diseases.

Researchers develop novel strategy for TB vaccine (post)

WEST LAFAYETTE, Ind. and HOUSTON, August 20, 2021 – Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis.

Scientists find clues to TB progression in gene expression (post)

Researchers at the Francis Crick Institute working with collaborators at the University of Leicester have identified how gene expression changes during different stages of tuberculosis (TB), including early after infection before any symptoms are clinically detectable.

Scientists discover how TB controls its growth, revealing new ways to fight the global disease (post)

New research has shown that Mycobacterium tuberculosis (MTB) controls its growth by modifying its DNA. 

Latest TB research publications (post)

Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, TB, and hepatitis C (post)

Geneva, 21 September 2021 – The Medicines Patent Pool (MPP) today announced that it has signed a licence agreement with Tandem Nano Ltd (TNL), the University of Liverpool (UoL) start-up focused on the development of its proprietary long-acting nanosystems platform technology. The non-exclusive, worldwide licence covers the patents and expertise of promising long-acting injectable technologies (LAIs) that could be applied in three disease areas with a high prevalence in low- and middle-income countries (LMICs): malaria, tuberculosis (TB), and hepatitis C (HCV). The candidate LAIs, currently developed by the Centre of Excellence for Long-acting Therapeutics (CELT) based at UoL, could provide optimal doses of medicines for malaria chemoprophylaxis, TB prevention, and HCV cure. The research teams are designing medicines to be delivered through a single injection to achieve the desired effect on the pathogens over prolonged periods, suppressing the need for daily oral pills, among many other advantages at the individual and the community levels.

Fresh hope for improving treatments for deadly lung disease (post)

Tuberculosis (TB) is still one of the biggest infectious killers in the world. Multiple drug resistant (MDR) TB has become a global health emergency, an emerging European crisis, and an important Irish public health concern. Many challenges remain in the global fight against this disease including a clinical need for effective treatments against MDR-TB.

STriTuVaD clinical trial of RUTI® vaccine for TB: First patient recruited at AIIMS, India (post)

The STriTuVaD Consortium is proud to announce the recruitment of the first patient in the STriTuVaD clinical trial of RUTI® vaccine for tuberculosis (TB)

Mycobacterium tuberculosis may induce resistance to secondary SARS-CoV-2 infection (post)

A team of United States-based scientists recently conducted a study to evaluate the effect of Mycobacterium tuberculosis infection on the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

How the pathogen Mycobacterium tuberculosis secretes and trafficks its only known exotoxin (post)

Six years ago, Michael Niederweis, Ph.D., described the first known toxin of the deadly pathogen Mycobacterium tuberculosis (Mtb), an exotoxin that had gone undetected for 132 years.